Company Filing History:
Years Active: 1996-1997
Title: Kevin Matthew Gorman: Innovator in Monoclonal Antibody Technology
Introduction
Kevin Matthew Gorman is a notable inventor based in Rochester, NY (US). He has made significant contributions to the field of monoclonal antibodies, with a focus on their applications in diagnostics and therapeutics. With a total of 2 patents, Gorman's work has the potential to impact various medical and clinical practices.
Latest Patents
Gorman's latest patents include innovative developments in monoclonal antibodies. One patent describes inhibitors and anti-inhibitor monoclonal antibodies that are highly specific for horseradish peroxidase. This invention features two groups of antibodies: one that inhibits at least about 95% of the normal activity of horseradish peroxidase when bound to the enzyme, and another that inhibits less than about 20% of the enzymatic activity but prevents the binding of the first group of antibodies. These antibodies can be conjugated to specific binding ligands such as drugs or hormones.
Another patent focuses on separation-free specific binding assays using anti-inhibitor antibodies. This assay allows for the detection of specific binding ligands through an immobilized receptor for the ligand, a reporter enzyme, an inhibitor antibody, and an anti-inhibitor antibody. The inhibitor antibody effectively shuts down the activity of the reporter enzyme when complexed, while the anti-inhibitor antibody binds to the reporter enzyme without affecting its activity. This innovative approach provides a direct correlation of the target specific binding ligand to the signal generated without the need for separation or wash steps.
Career Highlights
Kevin Matthew Gorman is currently employed at Johnson & Johnson Clinical Diagnostics, Inc. His work at this esteemed company has allowed him to further develop his expertise in monoclonal antibody technology and its applications in clinical diagnostics.
Collaborations
Throughout his career, Gorman has collaborated with notable colleagues, including John L Daiss and Carolyn R Hinchman. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Kevin Matthew Gorman is a distinguished inventor whose work in monoclonal antibodies has the potential to revolutionize diagnostic and therapeutic practices. His innovative patents and collaborations highlight his commitment to advancing medical science.